Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$55.63 USD

55.63
1,756,452

+0.18 (0.33%)

Updated Nov 5, 2024 11:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.

Pfizer (PFE) Q1 Earnings Beat, COVID Jab Sales Down as Expected

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q1 earnings and sales. Revenues from its COVID-19 vaccine, Comirnaty declined, as expected.

Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales

by Zacks Equity Research

Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.

Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bristol Myers Squibb (BMY) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 3.54% and 2.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings

by Mark Vickery

Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.

Ahan Chakraborty headshot

Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More

by Ahan Chakraborty

Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.

Should You Buy Bristol Myers Squibb (BMY) Ahead of Earnings?

by Zacks Equity Research

Bristol Myers Squibb (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx

by Zacks Equity Research

Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx are included in this Analyst Blog.

Sheraz Mian headshot

Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic & Altria Group

by Sheraz Mian

Q1 Earnings Season Scorecard is included in today's Research Daily in addition to new research reports on Bristol-Myers (BMY), Medtronic(MDT) and Altria Group (MO).

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Bristol-Myers (BMY) to Report Q1 Earnings: What+'s in Store?

by Zacks Equity Research

Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q1 results.

Earnings Preview: Vertex Pharmaceuticals (VRTX) Q1 Earnings Expected to Decline

by Zacks Equity Research

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Legend (LEGN) Stock Up 20% on Data Leak From Blood Cancer Study

by Zacks Equity Research

Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progression. Stock jumps 20% following the news.

Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Wins Patent Appeal for Blockbuster Psoriasis Drug

by Zacks Equity Research

The Appeal Court's decision upholding the patents for Amgen's (AMGN) blockbuster psoriasis drug Otezla will prevent drug-makers from selling a generic version till February 2028.

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $69.86, moving -0.53% from the previous trading session.

Bristol Myers (BMY), TSVT Application for Abecma Accepted

by Zacks Equity Research

Bristol Myers (BMY) and partner TSVTs sBLA for CAR T cell therapy is accepted by the FDA for earlier lines of treatment in multiple myeloma.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $70.69, marking a +0.68% move from the previous day.

Exelixis (EXEL) Surges 25.4% so Far in 2023: Here's Why

by Zacks Equity Research

Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Will Bristol Myers (BMY) Gain From New Drugs' Label Expansion?

by Zacks Equity Research

Label expansion of Bristol Myers' (BMY) new drugs should help it somewhat combat the decline in Revlimid sales due to generic competition.

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.